New Evidence for Iliac Vein Stenting: The C-TRACT Trial

For years, clinicians have utilized iliac vein stenting to treat Postthrombotic Syndrome (PTS) based largely on clinical intuition. However, high-level evidence has been scarce—until now.

Data from the C-TRACT trial, recently published in the New England Journal of Medicine, provides the validation needed to refine our endovascular approach to obstructed iliac veins.

---

Key Clinical Findings

The study randomized 225 patients with moderate-to-severe PTS to either endovascular therapy (stenting plus enhanced antithrombotics) or standard care. At 6 months, the interventional arm demonstrated:

• Symptom Reduction: Significantly improved scores on the Venous Clinical Severity Score (VCSS), showing a 2-point benefit over control (P = 0.001).

• Quality of Life: A robust 14.5-point increase in VEINES-QOL scores, indicating a meaningful impact on daily functionality.

• Device Performance: The benefits appear to be a class effect across approved venous stents, including Abre and Venovo.

The Trade-off: Bleeding Risk

The primary complication was a higher rate of bleeding events (11.6% vs. 3.6%; $P = 0.03$). These were predominantly nonmajor and likely linked to the intensified antithrombotic therapy required post-procedure, rather than the stenting procedure itself.

---

Practice Implications

The C-TRACT results move the needle toward evidence-based intervention. However, success hinges on individualized care. Shared decision-making is essential to balance substantial quality-of-life gains against bleeding risks and the need for long-term surveillance.